ADGRL2 and neoplasm: Interestingly, the larger effect on poor tumor response is in the GRIK1 gene (rs363599) as it is positively associated with × 1.33 greater tumor burden despite paclitaxel treatment (95% CI 0.39, 2.227, p = 0.047) (Table 3), followed by × 0.78 in LPHN2 (rs371363) (95% CI 0.24, 1.33, p = 0.005).